Cumberland Pharmaceuticals Inc. (CPIX)

factsheet Factsheet
  • Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $33 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-1 Mln

Cumberland Pharmaceuticals Inc. (CPIX) Share Price

$2.12

As on 01-Mar-2024 16:00 EST

up-down-arrow $-0.01-0.47%

  • Prev Close info

    $2.13

  • Day's Openinfo

    $2.15

  • Today's Highinfo

    $2.21

  • Today's Lowinfo

    $2.12

  • Today's Volumeinfo

    7,339

  • 52 Week rangeinfo

    $1.43 - 2.56

Please wait...

Cumberland Pharmaceuticals Inc. (CPIX) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Cumberland Pharmaceuticals (CPIX)
18.44 1.92 29.27 -7.83 -14.57 -15.97 -7.51
S&P BSE Healthcare*
10.81 3.72 14.71 61.24 18.27 20.28 12.42
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 01-Mar-2024  |  *As on 02-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Cumberland Pharmaceuticals (CPIX)
-20.44 -51.82 58.31 -42.72 -14.59 -17.98 33.82
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Healthcare
36.97 -12.10 20.87 61.45 -3.55 -5.89 0.49

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Cumberland Pharmaceuticals Inc. (CPIX) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Cumberland Pharmaceuticals Inc. (CPIX)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Cumberland Pharmaceuticals Inc. (CPIX)

        Founder, Chairman, President & CEO

        Mr. A. J. Kazimi MBA

        Chief Financial Officer

        Mr. John Michael Hamm

        Headquarters

        Nashville, TN

        FAQs for Cumberland Pharmaceuticals Inc. (CPIX)

        The total asset value of Cumberland Pharmaceuticals Inc. (CPIX) stood at $ 115 Mln as on 30-Sep-23

        The share price of Cumberland Pharmaceuticals Inc. (CPIX) is $2.12 (NASDAQ) as of 01-Mar-2024 16:00 EST. Cumberland Pharmaceuticals Inc. (CPIX) has given a return of -14.57% in the last 3 years.

        Cumberland Pharmaceuticals Inc. (CPIX) has a market capitalisation of $ 33 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Cumberland Pharmaceuticals Inc. (CPIX) is 0.91 times as on 29-Feb-2024, a -0.73% premium to its peers’ median range of 3.43 times.

        Since, TTM earnings of Cumberland Pharmaceuticals Inc. (CPIX) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Cumberland Pharmaceuticals Inc. (CPIX) and enter the required number of quantities and click on buy to purchase the shares of Cumberland Pharmaceuticals Inc. (CPIX).

        Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee. Address: 1600 West End Avenue, Nashville, TN, United States, 37203

        The CEO & director of Mr. A. J. Kazimi MBA. is Cumberland Pharmaceuticals Inc. (CPIX), and CFO & Sr. VP is Mr. John Michael Hamm.

        The promoters of Cumberland Pharmaceuticals Inc. (CPIX) have pledged 0% of the total equity as on Sep-23.

        Cumberland Pharmaceuticals Inc. (CPIX) Ratios
        Return on equity(%)
        -6.58
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.36
        Dividend yield(%)
        0

        No, TTM profit after tax of Cumberland Pharmaceuticals Inc. (CPIX) was $-1 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $32.79 Mln
        • Revenue (TTM)revenue-information $39.32 Mln
        • Earnings (TTM) earning-information $-0.70 Mln
        • Cash date-information $18.51 Mln
        • Total Debt info $18.65 Mln
        • Insider's Holding 44.81%
        • Liquidity liquidity Moderate
        • 52 Week range week-range $1.43 - 2.56
        • Shares outstanding share-outstanding 14,904,800
        • 10 Years Aggregate:

          CFO: $47.65 Mln

          EBITDA: $-1.78 Mln

          Net Profit: $-42.24 Mln

        About The Company

        • IPO Date 11-Aug-2009
        • Founder, Chairman, President & CEO Mr. A. J. Kazimi MBA
        • Chief Financial Officer Mr. John Michael Hamm
        • Listing key-listing NASDAQ: CPIX
        • Country United States
        • Headquarters headquarters Nashville, TN
        • Website website https://www.cumberlandpharma.com
        • Business

          Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and...  internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee. Address: 1600 West End Avenue, Nashville, TN, United States, 37203  Read more

        share-fund-plan-icon